Compare Global X MSCI Argentina ETF (ARGT) vs 10X Genomics Inc (TXG) Price & Performance

ARGT trades at $92.96, up 0.43% with a bearish technical signal from moving averages. The ETF shows neutral oscillators with RSI at 44.95. Recent Seeking Alpha analysis (June 18, 2026) highlights a 28% upside potential as Argentina's economic reforms progress, with the fund trading at 12.5x earnings below its post-Milei average.

The outlook suggests potential re-rating to 14-18x earnings could yield 12-44% upside, supported by Argentina's improving monetary backdrop. Key risks include country-specific volatility and concentrated holdings in MercadoLibre. Institutional interest is growing with Stanley Druckenmiller's recent position accumulation.

TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.

The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.